凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
海普瑞(002399)公告正文

海普瑞:2019年第一季度报告全文

公告日期 2019-04-30
股票简称:海普瑞 股票代码:002399
               深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文




深圳市海普瑞药业集团股份有限公司

       2019 年第一季度报告




          2019 年 04 月




                1
                                 深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人李锂、主管会计工作负责人张斌及会计机构负责人(会计主管人

员)张斌声明:保证季度报告中财务报表的真实、准确、完整。




                                  2
                                                        深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文




                                       第二节 公司基本情况

一、主要会计数据和财务指标

公司是否需追溯调整或重述以前年度会计数据
√ 是 □ 否
追溯调整或重述原因
同一控制下企业合并

                                                                                                      本报告期比上年同
                                                                              上年同期
                                            本报告期                                                         期增减

                                                                     调整前              调整后              调整后

营业收入(元)                               1,023,118,395.29     798,062,177.39    959,291,558.46                    6.65%

归属于上市公司股东的净利润(元)              507,033,390.57       41,988,171.45     68,850,444.57               636.43%

归属于上市公司股东的扣除非经常性损
                                               10,710,525.69       36,618,514.59     62,580,858.12               -82.89%
益的净利润(元)

经营活动产生的现金流量净额(元)              -138,180,573.42      -48,225,972.78   -76,542,880.09               -80.53%

基本每股收益(元/股)                                   0.4065            0.0337             0.0552              636.41%

稀释每股收益(元/股)                                   0.4065            0.0337             0.0552              636.41%

加权平均净资产收益率                                    8.00%              0.56%              0.88%                   7.12%

                                                                                                      本报告期末比上年
                                                                              上年度末
                                           本报告期末                                                     度末增减

                                                                     调整前              调整后              调整后

                                                                 13,655,079,889.3 13,655,079,889.3
总资产(元)                                13,443,223,483.47                                                     -1.55%
                                                                                5                 5

归属于上市公司股东的净资产(元)             6,613,929,643.44 6,068,025,668.64 6,068,025,668.64                       9.00%

非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                                 单位:元

                         项目                               年初至报告期期末金额                      说明

                                                                                         持有君圣泰股权比例下降,对其
非流动资产处置损益(包括已计提资产减值准备的冲销部分)                  573,437,121.09 核算由成本法转权益法而确认
                                                                                         的一次性投资收益

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                          3,816,442.03
一标准定额或定量享受的政府补助除外)

除同公司正常经营业务相关的有效套期保值业务外,持有交易
                                                                          6,436,688.49
性金融资产、衍生金融资产、交易性金融负债、衍生金融负债


                                                        3
                                                         深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


产生的公允价值变动损益,以及处置交易性金融资产、衍生金
融资产、交易性金融负债、衍生金融负债和其他债权投资取得
的投资收益

除上述各项之外的其他营业外收入和支出                                        283,040.70

减:所得税影响额                                                          87,611,617.25

       少数股东权益影响额(税后)                                             38,810.18

合计                                                                     496,322,864.88              --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东总数和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                               单位:股

                                                   报告期末表决权恢复的优先股股
报告期末普通股股东总数                    21,804                                                                    0
                                                   东总数(如有)

                                                前 10 名股东持股情况

                                                                     持有有限售条件           质押或冻结情况
     股东名称          股东性质      持股比例         持股数量
                                                                       的股份数量         股份状态        数量

深圳市乐仁科技
                    境内非国有法人        38.01%       474,029,899                  0
有限公司

乌鲁木齐金田土
股权投资合伙企 境内非国有法人             32.72%       408,041,280                  0
业(有限合伙)

乌鲁木齐水滴石
穿股权投资合伙 境内非国有法人              3.72%        46,425,600                  0
企业(有限合伙)

乌鲁木齐飞来石
股权投资有限公 境内非国有法人              3.23%        40,320,000                  0 质押                27,400,000


深圳市海普瑞药
业股份有限公司
                    其他                   1.21%        15,118,035                  0
-第二期员工持
股计划

#深圳德威资本       其他                   0.72%         8,919,700                  0


                                                          4
                                                       深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


投资管理有限公
司-德威资本优
盛私募基金

黄光伟            境内自然人               0.69%        8,654,100              0

黄镇              境内自然人               0.68%        8,500,000              0

应一城            境内自然人               0.39%        4,908,402              0

刘桂波            境内自然人               0.36%        4,472,865              0

                                          前 10 名无限售条件股东持股情况

                                                                                            股份种类
              股东名称                       持有无限售条件股份数量
                                                                                    股份种类           数量

深圳市乐仁科技有限公司                                                474,029,899 人民币普通股         474,029,899

乌鲁木齐金田土股权投资合伙企
                                                                      408,041,280 人民币普通股         408,041,280
业(有限合伙)

乌鲁木齐水滴石穿股权投资合伙
                                                                       46,425,600 人民币普通股          46,425,600
企业(有限合伙)

乌鲁木齐飞来石股权投资有限公
                                                                       40,320,000 人民币普通股          40,320,000


深圳市海普瑞药业股份有限公司
                                                                       15,118,035 人民币普通股          15,118,035
-第二期员工持股计划

#深圳德威资本投资管理有限公司
                                                                        8,919,700 人民币普通股           8,919,700
-德威资本优盛私募基金

黄光伟                                                                  8,654,100 人民币普通股           8,654,100

黄镇                                                                    8,500,000 人民币普通股           8,500,000

应一城                                                                  4,908,402 人民币普通股           4,908,402

刘桂波                                                                  4,472,865 人民币普通股           4,472,865

                                深圳市乐仁科技有限公司和乌鲁木齐金田土股权投资合伙企业(有限合伙)的股东(合
                                伙人)为李锂和李坦,乌鲁木齐飞来石股权投资有限公司的股东为李锂,乌鲁木齐水滴
                                石穿股权投资合伙企业(有限合伙)的合伙人为单宇和李坦,李锂和李坦为夫妻关系,
上述股东关联关系或一致行动的
                                单宇和李坦为兄妹关系,单宇参与公司第二期员工持股计划,参加份额为 38.88%。黄
说明
                                光伟和黄镇为叔侄关系。除上述情况外,公司未知其他前十名股东之间是否存在关联关
                                系,也未知是否属于一致行动人;公司未知其他前十名无限售条件股东之间是否存在关
                                联关系,也未知是否属于一致行动人。

                                前 10 名普通股股东中,黄光伟通过中国中投证券有限责任公司客户信用交易担保证券
前 10 名普通股股东参与融资融券 账户持有公司股票 8,654,100 股,占公司总股本的 0.69%;黄镇通过中国中投证券有限
业务情况说明(如有)            责任公司客户信用交易担保证券账户持有公司股票 8,500,000 股,占公司总股本的
                                0.68%。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否



                                                        5
                                                     深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                      6
                                                 深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文




                                    第三节 重要事项

一、报告期主要财务数据、财务指标发生变动的情况及原因

√ 适用 □ 不适用
资产负债表项目

             项目            本报告期末         本报告期初           同比增减                   变动原因
                                                                                     报告期内偿还银行借款和支付投
货币资金                     1,280,300,092.57   2,121,745,382.45         -39.66%
                                                                                     资款所致
                                                                                     报告期内执行新金融工具准则所
交易性金融资产                 109,373,757.70                                   --
                                                                                     致
以公允价值计量且其变动计入                                                           报告期内执行新金融工具准则所
                                                  79,215,975.24         -100.00%
当期损益的金融资产                                                                   致
其他流动资产                   186,850,503.66    366,908,620.97          -49.07% 报告期内赎回理财产品所致
                                                                                     报告期内执行新金融工具准则所
可供出售金融资产                                1,604,576,638.19        -100.00%
                                                                                     致
                                                                                     报告期内丧失对君圣泰的控制
                                                                                     权,对剩余股权由成本法转为权
长期股权投资                 1,132,230,071.26    467,291,507.14         142.30%
                                                                                     益法核算,并按照丧失控制权日
                                                                                     公允价值调整剩余股权价值。
                                                                                     报告期内执行新金融工具准则所
其他权益工具投资             1,376,059,939.37                                   --
                                                                                     致
                                                                                     报告期内执行新金融工具准则所
其他非流动金融资产             370,642,721.53                                   --
                                                                                     致
                                                                                     报告期内合并范围减少君圣泰,
开发支出                          346,608.84      15,376,337.08          -97.75% 转出君圣泰的开发支出的余额所
                                                                                     致
                                                                                     报告期内发放上年度年终奖金所
应付职工薪酬                    82,249,772.40    128,119,602.66          -35.80%
                                                                                     致
一年内到期的非流动负债           7,234,558.72    485,009,829.14          -98.51% 报告期内偿还银行借款所致



利润表项目

               项目           本报告期            上年同期           同比增减                   变动原因
                                                                                     报告期内母公司经主管税局核准
税金及附加                       2,615,426.89         3,992,408.40       -34.49% 的当期免抵的增值税税额较上年
                                                                                     同期减少所致
                                                                                     报告期内孙公司天道医药的研发
研发费用                        39,576,899.12     60,962,696.54          -35.08%
                                                                                     费用减少所致
财务费用                       106,377,729.98     81,017,684.73          31.30% 报告期内利息收入减少、利息支



                                                  7
                                               深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


                                                                                   出增加以及汇兑损失增加共同导
                                                                                   致
                                                                                   报告期内收到的政府补助减少所
其他收益                        3,816,442.03        7,403,894.58       -48.45%
                                                                                   致
                                                                                   报告期内丧失君圣泰控制权、对
                                                                                   其由成本法转权益法核算而确认
                                                                                   的一次性投资收益,以及报告期
投资收益                      515,826,217.23    -9,449,376.32        5558.84%
                                                                                   对RVX等公司股权按照权益法核
                                                                                   算确认的投资损失 增加共同导
                                                                                   致。
                                                                                   报告期内Prometic股票公允价值
公允价值变动收益                4,013,061.75                                  --
                                                                                   变动所致
                                                                                   主要为报告期内投资收益增加所
营业利润                      580,555,945.28   100,527,234.39         477.51%
                                                                                   致
                                                                                   报告期内孙公司SPL的杂项收入
营业外收入                       493,097.48         1,461,063.16       -66.25%
                                                                                   减少所致
利润总额                      580,828,899.53   101,978,841.49         469.56% 报告期内营业利润增加所致
                                                                                   报告期内丧失君圣泰控制权取得
所得税费用                     86,280,120.91    30,617,586.13         181.80% 的投资收益确认递延所得税费用
                                                                                   所致
净利润                        494,548,778.62    71,361,255.36         593.02% 报告期内利润总额增加所致
归属于母公司股东的净利润      507,033,390.57    68,850,444.57         636.43% 报告期内净利润增加所致
                                                                                   主要为减少了多普乐少数股东损
少数股东损益                  -12,484,611.95        2,510,810.79      -597.23%
                                                                                   益所致



现金流量表项目

             项目            本报告期          上年同期            同比增减                   变动原因

                                                                                   报告期内购买商品、接受劳务支
经营活动产生的现金流量净额   -138,180,573.42   -76,542,880.09          -80.53% 付的现金和支付给职工以及为职
                                                                                   工支付的现金同比增加所致

                                                                                   报告期内投资支付的现金同比增
投资活动产生的现金流量净额    -99,612,740.75   -65,701,463.87          -51.61% 加的金额大于投资收回的现金同
                                                                                   比增加的金额所致

                                                                                   报告期内偿还银行借款支付的现
筹资活动产生的现金流量净额   -593,869,140.67   125,145,232.83         -574.54% 金大于向银行借款收到的现金所
                                                                                   致

汇率变动对现金及现金等价物                                                         报告期内人民币升值,但升值的
                               -6,051,105.36    -9,565,708.94          36.74%
的影响                                                                             幅度小于上年同期所致

                                                                                   报告期内经营活动产生的现金流
现金及现金等价物净增加额     -837,713,560.20   -26,664,820.07        -3041.64% 量净额减少,投资活动产生的现
                                                                                   金流量净额减少和筹资活动产生


                                                8
                                                     深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


                                                                                的现金流净额减少共同所致




二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用

     1、2015年3月18日,公司第三届董事会第八次会议审议通过了《关于设立产业并购基金的议案》,决
定设立深圳市德康投资发展有限公司,注册资本1,000万元。德康投资与北京鑫羊投资管理有限责任公司、
北京格兰德丰投资管理中心(有限合伙)等共同成立北京枫海资本管理中心(有限合伙),枫海资本认缴
出资总额250万元。待枫海资本成立后,再由该枫海资本作为普通合伙人,海普瑞使用不超过2.5亿元的自
有资金作为有限合伙人参与设立“深圳枫海资本并购基金(有限合伙)”。截至本公告日,公司已累计支付
20,943.17万元人民币。
     2、2016年6月16日,公司第三届董事会第二十二次会议审议通过《关于公司使用自有资金对TPG
BIOTECHNOLOGY PARTNERS V, L.P. 投资的议案》,同意使用6,000万美元自有资金参与投资TPG
Biotechnology Partners V, L.P.。详细容参见2016年6月17日刊登于《证券时报》、《中国证券报》、《上海
证 券 报 》 、 《 证 券 日 报 》 和 巨 潮 资 讯 网 www.cninfo.com.cn 的 《 关 于 公 司 使 用 自 有 资 金 对 TPG
BIOTECHNOLOGY PARTNERS V, L.P.投资的公告》。截至本公告日,公司已累计支付3,745.25万美元。
     3、2016年9月20日,第三届董事会第二十六次会议审议通过了《关于对全资子公司海普瑞(香港)有
限公司进行增资的议案》,同意公司以自有资金5,500万美元(或等值人民币)增加对香港海普瑞的投资,
详细内容参见2016年9月21日刊登于《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和
巨潮资讯网 www.cninfo.com.cn 的《关于对全资子公司海普瑞(香港)有限公司进行增资的公告》。截至
本公告日,该项增资尚未完成。
     4、2016年11月18日,第三届董事会第二十八会议审议通过了《关于对全资子公司Hepalink USA Inc.增
资的议案》,同意公司以自有资金折合人民币5亿元增加对美国海普瑞的投资,详细内容参见2016年11月
19日刊登于《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn
的《关于对全资子公司Hepalink USA Inc.增资的公告》。截至本公告日,该项增资尚未完成。
     5、2018年8月,海普瑞与Aridis对合资子公司瑞迪生物增资,详细内容参见2018年8月15日刊登于《证
券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于
控股子公司取得产品授权暨对控股子公司增资的公告》。瑞迪生物于2019年1月收到深圳市市场监督管理
局发出的变更(备案)通知书,瑞迪生物的注册资本由11,760,000美元变更为14,117,647美元,变更前后公
司和Aridis的认缴出资比例不变。详细内容参见2019年1月5日刊登于《证券时报》、《中国证券报》、《上
海证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《对控股子公司增资的进展公告》。
     6、2018年7月9日,公司第四届董事会第十五次会议审议通过了《关于公开发行公司债券方案的议案》、
《关于非公开发行公司债券方案的议案》,上述议案经2018年7月26日召开的2018年第三次临时股东大会
审议通过。2018年12月,公司非公开发行公司债券获深圳证券交易所出具的《关于深圳市海普瑞药业集团
股份有限公司2018年非公开发行公司债券符合深交所转让条件的无异议函》(证监许可[2018]723号)。2019
年1月,公司向合格投资者公开发行公司债券获得中国证券监督管理委员会出具的《关于核准深圳市海普
瑞药业集团股份有限公司向合格投资者公开发行公司债券的批复》(证监许可[2019]28号)。详细内容参
见2019年1月26日刊登于《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网
www.cninfo.com.cn 的《关于公司发行公司债券申请获中国证券监督管理委员会核准的公告》。
     7、根据深圳证券交易所《关于深圳市海普瑞药业集团股份有限公司2018年非公开发行公司债券符合深
交所转让条件的无异议函》(深证函〔2018〕723号),公司获准非公开发行面值总额不超过人民币7亿元
的公司债券(以下简称“本次公司债券”)。
     为增强本次公司债券的偿债保障,节约公司的财务成本,公司与深圳市高新投集团有限公司(以下简

                                                      9
                                                       深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


称“深圳高新投”)签署协议,其为本次公司债券的按期还本付息提供连带责任保证担保。公司实际控制人
李锂作为保证人向深圳高新投提供反担保。同时,公司与深圳高新投签署《反担保抵押合同》,反担保范
围为《担保协议书》项下应由公司承担的全部债务及《反担保抵押合同》项下由深圳高新投垫付的其他费
用,反担保期间为债务履行期限届满之日起两年。公司用于抵押的财产为公司及全资子公司持有的部分不
动产(产权证编号:粤2017深圳市不动产权第0167966号、深房地字第4000457007号、深房地字第4000432648
号)。该事项已经公司2019年第一次临时股东大会审议通过。
     2019年4月22日,公司完成了深圳市海普瑞药业集团股份有限公司2019年非公开发行公司债券(证券简
称“19海普瑞”,证券代码“114455”,以下简称“本期债券”)的发行。债券的发行期间为2019年4月19日至2019
年4月22日,实际募集资金7亿元,最终票面利率为5.5%。
     8、2018年8月27日,第四届董事会第第十六次会议审议通过《关于变更深圳君圣泰生物技术有限公司
股权架构调整方案的议案》,同意将公司直接持有的深圳君圣泰生物技术有限公司(以下简称“深圳君圣
泰”)的股权转让给HighTideTherapeutics(HongKong)Limited(以下简称“香港君圣泰”),并同意公司以人
民币7,900万元对开曼君圣泰增资。公司第四届董事会第十七次会议通过了《关于控股子公司对外融资暨放
弃优先认购权的议案》,同意开曼君圣泰进行总额为1,300万美元的B-1轮股权融资,公司放弃对开曼君圣
泰的同比例优先认购权。2019年1月,公司向香港君圣泰转让所持的深圳君圣泰股权、向开曼君圣泰增资
事项已完成必要的审批备案和工商变更登记手续,并收到开曼君圣泰发出的股份证书。此外,开曼君圣泰
B-1轮股权融资的交易对方已经完成缴款。详细内容参见2019年1月18日刊登于《证券时报》、《中国证券
报》、《上海证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于控股子公司股权架构调
整及对外融资的进展公告》。截至本公告日,公司对开曼君圣泰持股比例为48.74%,不再将开曼君圣泰及
其子公司纳入合并范围。
     9、员工持股计划
     2018年12月11日,第四届董事会第十九次会议审议通过《关于公司第三期员工持股计划(草案)及摘
要的议案》,该议案经2018年12月28日召开的2018年第五次临时股东大会审议通过。该期员工持股计划已
于2019年2月1日完成股票购买,共计3,886,264股,占公司总股本的比例为0.31%,锁定期为2019年2月2日
至2020年2月1日,存续期自2018年12月28日至2020年12月27日。详细内容参见2019年2月2日刊登于《证券
时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网 www.cninfo.com.cn 的《关于第
三期员工持股计划完成股票购买的公告》。
     公司于2016年11月25日召开第三届董事会第二十九次会议审议通过了《关于公司第二期员工持股计划
(草案)及摘要的议案》,并于2016年12月12日经公司2016年第三次临时股东大会审议通过。该期员工持
股计划已于2017年3月9日完成股票购买,共计20,618,035股,占公司总股本的比例为1.65%,参与该期员工
持股计划的员工共229人,包括公司及下属控股子公司的董事(不含独立董事、外部董事)、监事(不含
外部监事)、高级管理人员和核心员工。锁定期自2017年3月11日至2018年3月10日,存续期自2016年12月
12日至2019年12月11日。截至本公告日,公司二期员工持股计划已卖出5,500,000股,剩余15,118,035股。


            重要事项概述                            披露日期                   临时报告披露网站查询索引

                                                                          2018-068《关于控股子公司取得产品授权
                                     2018 年 08 月 15 日                  暨对控股子公司增资的公告》,巨潮资讯
公司与 Aridis 设立合资子公司的公告                                        网

                                                                          2019-001《对控股子公司增资的进展公
                                     2019 年 01 月 05 日
                                                                          告》,巨潮资讯网

                                                                          2018-057《第四届董事会第十五次会议决
公开发行公司债券、非公开发行公司债 2018 年 07 月 10 日
                                                                          议公告》,巨潮资讯网

                                     2018 年 07 月 26 日                  2018-066《2018 年第三次临时股东大会


                                                           10
                                                        深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


                                                                                   决议公告》,巨潮资讯网

                                                                                   2019-003《关于向合格投资者公开发行公
                                      2019 年 01 月 26 日                          司债券获得中国证券监督管理委员会核
                                                                                   准批复的公告》,巨潮资讯网

                                                                                   2019-018《关于 2019 年非公开发行公司
                                      2019 年 04 月 23 日
                                                                                   债券发行结果的公告》,巨潮资讯网

                                                                                   2018-073《关于变更深圳君圣泰生物技术
                                      2018 年 08 月 29 日                          有限公司股权架构调整方案的公告》,巨
                                                                                   潮资讯网
变更深圳君圣泰生物技术有限公司股权
                                                                                   2018-079《关于控股子公司对外融资暨放
架构调整方案                          2018 年 09 月 26 日
                                                                                   弃优先认购权的公告》,巨潮资讯网

                                                                                   2019-002《关于控股子公司股权架构调整
                                      2019 年 01 月 18 日
                                                                                   及对外融资的进展公告》,巨潮资讯网

                                                                                   2018-093《第三期员工持股计划(草案)
                                      2018 年 12 月 11 日
                                                                                   摘要》,巨潮资讯网

                                                                                   2019-004《关于第三期员工持股计划完成
第三期员工持股计划的相关事项          2019 年 01 月 29 日
                                                                                   股票购买的公告》,巨潮资讯网

                                                                                   2019-005《关于第三期员工持股计划完成
                                      2019 年 02 月 02 日
                                                                                   股票购买的公告》,巨潮资讯网

股份回购的实施进展情况
□ 适用 √ 不适用
采用集中竞价方式减持回购股份的实施进展情况
□ 适用 √ 不适用


三、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行
完毕的承诺事项

√ 适用 □ 不适用

             承诺事由                承诺方       承诺类型         承诺内容        承诺时间        承诺期限        履行情况

股改承诺                         不适用

收购报告书或权益变动报告书中所
                                 不适用
作承诺

                                 李锂;李坦;                    多普乐 2018
                                 单宇;深圳市                    年、2019 年和
                                 乐仁科技有                      2020 年扣除                                      正常履行中,
                                                                                                 2018 年 1 月 1
                                 限公司;乌鲁 业绩承诺及         非经常性损      2018 年 02 月                    2018 年度业
资产重组时所作承诺                                                                               日至 2020 年
                                 木齐飞来石     补偿安排         益后的净利      11 日                            绩承诺已实
                                                                                                 12 月 31 日
                                 股权投资有                      润分别不低                                       现。
                                 限公司;乌鲁                    于 19,060.00
                                 木齐金田土                      万元、


                                                            11
                                                     深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


                               股权投资合                    28,680.00 万
                               伙企业(有限                  元和
                               合伙);乌鲁                  34,080.00 万
                               木齐水滴石                    元;若多普乐
                               穿股权投资                    未实现上述
                               合伙企业(有                  承诺的净利
                               限合伙)                      润,则承诺方
                                                             分别以其在
                                                             本次交易中
                                                             所取得的对
                                                             价为限承担
                                                             业绩补偿义
                                                             务,并就前述
                                                             补偿义务承
                                                             担连带责任。

                                                             1、在本公司
                                                             作为公司控
                                                             股股东期间/
                                                             在本人作为
                                                             公司实际控
                                                             制人期间/在
                                                             本人作为公
                                                             司董事、总经
                                                             理期间,本公
                               深圳市乐仁                    司/本人保证
                               科技有限公                    不自营或以
                               司;乌鲁木齐                  合资、合作等
                               飞来石股权                    方式经营任
                                              关于同业竞                                        报告期内,承
                               投资有限公                    何与公司现
                                              争、关联交                    2010 年 04 月       诺人严格履
首次公开发行或再融资时所作承诺 司;乌鲁木齐                  从事的业务
                                              易、资金占用                  23 日               行了上述承
                               金田土股权                    有竞争的业
                                              方面的承诺                                        诺。
                               投资合伙企                    务,本公司现
                               业(有限合                    有的或将来
                               伙);李锂;                  成立的全资
                               李坦;单宇                    子公司、控股
                                                             子公司以及
                                                             其他受本公
                                                             司控制的企
                                                             业亦不会经
                                                             营与公司现
                                                             从事的业务
                                                             有竞争的业
                                                             务。2、如违
                                                             反上述承诺,


                                                      12
                      深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


                               本公司同意
                               承担给公司
                               造成的全部
                               损失。

                               1、如今后公
                               司或子公司
                               深圳市多普
                               生生物技术
                               有限公司因
                               依据深府
                               [1988]232
                               号文享受的
                               企业所得税
                               优惠被税务
                               机关撤消而
                               产生的额外
                               税项和费用
                               时,将及时、
                               无条件、全额
                               返还公司或
                               深圳市多普
深圳市乐仁
                               生生物技术
科技有限公
                               有限公司补                        报告期内,承
司;乌鲁木齐
                               缴的税款以     2010 年 04 月      诺人严格履
金田土股权     其他承诺
                               及因此所产     23 日              行了上述承
投资合伙企
                               生的所有相                        诺。
业(有限合
                               关费用。2、
伙)
                               如今后公司
                               因以实际缴
                               纳的增值税
                               和营业税税
                               额为计税依
                               据缴纳城市
                               维护建设税
                               和教育费附
                               加事宜被税
                               务机关追缴
                               而产生额外
                               税项和费用
                               时,将及时、
                               无条件、全额
                               返还公司补
                               缴的税款以
                               及因此所产


                          13
                                                               深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


                                                                       生的所有相
                                                                       关费用。

                                                                       如今后公司
                                                                       或子公司深
                                                                       圳市多普生
                                                                       生物技术有
                                                                       限公司因上
                                                                       市前执行住
                                                                       房公积金政
                                       深圳市乐仁
                                                                       策事宜被要
                                       科技有限公
                                                                       求补缴住房                               报告期内,承
                                       司;乌鲁木齐
                                                                       公积金、缴纳 2010 年 04 月               诺人严格履
                                       金田土股权     其他承诺
                                                                       罚款或因此     23 日                     行了上述承
                                       投资合伙企
                                                                       遭受任何损                               诺。
                                       业(有限合
                                                                       失时,将及
                                       伙)
                                                                       时、无条件、
                                                                       全额返还公
                                                                       司或深圳市
                                                                       多普生生物
                                                                       技术有限公
                                                                       司由此遭受
                                                                       的一切损失。

股权激励承诺                           不适用

其他对公司中小股东所作承诺             不适用

承诺是否按时履行                       是

如承诺超期未履行完毕的,应当详
细说明未完成履行的具体原因及下 无
一步的工作计划


四、对 2019 年 1-6 月经营业绩的预计

□ 适用 √ 不适用


五、以公允价值计量的金融资产

√ 适用 □ 不适用
                                                                                                                        单位:元

                                                计入权益的累
                    初始投资     本期公允价                    报告期内购入 报告期内售 累计投资收
    资产类别                                    计公允价值变                                            期末金额     资金来源
                      成本       值变动损益                           金额        出金额       益
                                                    动

                    1,084,520,                                                 11,415,546. 2,423,626.7 1,111,599,6
股票                             -5,922,308.23 27,079,369.26 107,497,373.02                                          自有资金
                       235.34                                                            78         4       04.60


                                                                 14
                                                               深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


                    709,479,84                                                                          665,260,838
基金                             -1,937,774.19 -44,219,004.21 31,082,992.84                                           自有资金
                          2.97                                                                                  .76

                                                                                                        79,215,975.
金融衍生工具                                   79,215,975.24                                                          其他
                                                                                                                24

                    1,794,000,                                                11,415,546. 2,423,626.7 1,856,076,4
合计                             -7,860,082.42 62,076,340.29 138,580,365.86                                                  --
                       078.31                                                         78            4         18.60


六、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、报告期内接待调研、沟通、采访等活动登记表

√ 适用 □ 不适用

        接待时间                        接待方式                 接待对象类型                   调研的基本情况索引

                                                                                       http://static.cninfo.com.cn/finalpage/201
2019 年 01 月 10 日          实地调研                     机构
                                                                                       9-01-11/1205766208.pdf

                                                                                       http://static.cninfo.com.cn/finalpage/201
2019 年 02 月 28 日          实地调研                     机构
                                                                                       9-03-01/1205870993.pdf

                                                                                       http://static.cninfo.com.cn/finalpage/201
2019 年 03 月 06 日          实地调研                     机构
                                                                                       9-03-07/1205884522.pdf

                                                                                       http://static.cninfo.com.cn/finalpage/201
2019 年 03 月 14 日          实地调研                     机构
                                                                                       9-03-15/1205901690.pdf




                                                               15
                                                    深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文




                                        第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:深圳市海普瑞药业集团股份有限公司
                                                                                                      单位:元

                  项目                       2019 年 3 月 31 日                 2018 年 12 月 31 日

流动资产:

    货币资金                                              1,280,300,092.57                   2,121,745,382.45

    结算备付金

    拆出资金

    交易性金融资产                                         109,373,757.70

    以公允价值计量且其变动计入当期
                                                                                                79,215,975.24
损益的金融资产

    衍生金融资产

    应收票据及应收账款                                    1,080,485,265.54                   1,085,011,935.13

      其中:应收票据                                          1,071,319.60                       1,270,000.00

               应收账款                                   1,079,413,945.94                   1,083,741,935.13

    预付款项                                               269,403,523.57                      209,074,315.90

    应收保费

    应收分保账款

    应收分保合同准备金

    其他应收款                                             176,856,908.72                      208,083,239.67

      其中:应收利息                                        69,488,709.10                       68,901,627.36

               应收股利

    买入返售金融资产

    存货                                                  1,583,848,218.71                   1,529,977,946.64

    合同资产

    持有待售资产

    一年内到期的非流动资产

    其他流动资产                                           186,850,503.66                      366,908,620.97

流动资产合计                                              4,687,118,270.47                   5,600,017,416.00



                                                     16
                                     深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


非流动资产:

    发放贷款和垫款

    债权投资

    可供出售金融资产                                                         1,604,576,638.19

    其他债权投资

    持有至到期投资

    长期应收款                                 8,927,355.91                      7,761,376.21

    长期股权投资                           1,132,230,071.26                    467,291,507.14

    其他权益工具投资                       1,376,059,939.37

    其他非流动金融资产                      370,642,721.53

    投资性房地产

    固定资产                               1,558,586,820.96                  1,607,503,760.60

    在建工程                                784,071,480.68                     743,775,565.82

    生产性生物资产

    油气资产

    使用权资产

    无形资产                                694,257,539.52                     729,843,416.78

    开发支出                                    346,608.84                      15,376,337.08

    商誉                                   2,272,981,228.99                  2,316,763,164.90

    长期待摊费用                            208,367,460.64                     212,857,482.57

    递延所得税资产                          221,629,135.06                     208,971,292.44

    其他非流动资产                          128,004,850.24                     140,341,931.62

非流动资产合计                             8,756,105,213.00                  8,055,062,473.35

资产总计                                  13,443,223,483.47                 13,655,079,889.35

流动负债:

    短期借款                               1,872,768,856.84                  1,981,491,046.35

    向中央银行借款

    拆入资金

    交易性金融负债

    以公允价值计量且其变动计入当期
损益的金融负债

    衍生金融负债

    应付票据及应付账款                      259,740,429.84                     334,974,579.29

    预收款项                                 99,270,934.65                      97,806,654.17




                                     17
                             深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


    卖出回购金融资产款

    吸收存款及同业存放

    代理买卖证券款

    代理承销证券款

    应付职工薪酬                    82,249,772.40                      128,119,602.66

    应交税费                        91,185,530.96                       82,201,143.51

    其他应付款                    1,394,547,584.97                   1,361,351,397.17

      其中:应付利息                23,247,407.23                       19,825,989.68

               应付股利

    应付手续费及佣金

    应付分保账款

    合同负债

    持有待售负债

    一年内到期的非流动负债           7,234,558.72                      485,009,829.14

    其他流动负债                    30,306,892.64                       33,519,201.97

流动负债合计                      3,837,304,561.02                   4,504,473,454.26

非流动负债:

    保险合同准备金

    长期借款                      1,331,925,467.93                   1,454,833,881.38

    应付债券                       995,073,224.79                      994,608,157.79

      其中:优先股

               永续债

    租赁负债

    长期应付款                       7,268,990.71                        7,788,409.10

    长期应付职工薪酬                64,975,846.09                       67,139,226.82

    预计负债                         9,518,269.42                        9,696,689.88

    递延收益                        22,369,556.46                       31,254,005.05

    递延所得税负债                 434,789,562.12                      340,539,461.52

    其他非流动负债

非流动负债合计                    2,865,920,917.52                   2,905,859,831.54

负债合计                          6,703,225,478.54                   7,410,333,285.80

所有者权益:

    股本                          1,247,201,704.00                   1,247,201,704.00

    其他权益工具



                             18
                                                  深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


      其中:优先股

             永续债

    资本公积                                             2,245,263,750.73                  2,254,181,696.10

    减:库存股

    其他综合收益                                          118,258,050.63                     108,981,640.76

    专项储备

    盈余公积                                              513,125,623.22                     517,566,569.56

    一般风险准备

    未分配利润                                           2,490,080,514.86                  1,940,094,058.22

归属于母公司所有者权益合计                               6,613,929,643.44                  6,068,025,668.64

    少数股东权益                                          126,068,361.49                     176,720,934.91

所有者权益合计                                           6,739,998,004.93                  6,244,746,603.55

负债和所有者权益总计                                    13,443,223,483.47                 13,655,079,889.35


法定代表人:李锂                     主管会计工作负责人:张斌                       会计机构负责人:张斌


2、母公司资产负债表

                                                                                                    单位:元

                 项目                      2019 年 3 月 31 日                 2018 年 12 月 31 日

流动资产:

    货币资金                                             1,024,773,967.46                  1,624,582,294.97

    交易性金融资产

    以公允价值计量且其变动计入当期
                                                          109,373,757.70                      79,215,975.24
损益的金融资产

    衍生金融资产

    应收票据及应收账款                                   1,530,285,177.02                  1,537,134,588.92

      其中:应收票据                                      146,071,319.60                      96,270,000.00

             应收账款                                    1,384,213,857.42                  1,440,864,588.92

    预付款项                                              606,577,790.15                     562,679,752.43

    其他应收款                                            951,579,119.74                     612,526,311.64

      其中:应收利息                                      226,255,449.25                     223,753,432.17

             应收股利

    存货                                                  336,763,585.81                     363,369,059.84

    合同资产

    持有待售资产


                                                   19
                                     深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


    一年内到期的非流动资产

    其他流动资产                                                               216,124,612.46

流动资产合计                              4,559,353,397.88                   4,995,632,595.50

非流动资产:

    债权投资

    可供出售金融资产                                                           473,911,545.02

    其他债权投资

    持有至到期投资

    长期应收款                             999,443,681.83                      961,534,320.00

    长期股权投资                          2,571,805,045.83                   2,548,598,518.15

    其他权益工具投资                       481,749,753.45

    其他非流动金融资产

    投资性房地产

    固定资产                               594,399,910.83                      603,513,778.11

    在建工程                               456,079,115.54                      437,425,211.96

    生产性生物资产

    油气资产

    使用权资产

    无形资产                                97,381,922.34                       98,637,382.26

    开发支出                                   349,562.15                         281,086.15

    商誉

    长期待摊费用                            92,401,432.34                       93,935,642.15

    递延所得税资产                          84,851,437.49                       66,767,066.28

    其他非流动资产                           4,197,179.83                        6,144,895.70

非流动资产合计                            5,382,659,041.63                   5,290,749,445.78

资产总计                                  9,942,012,439.51                  10,286,382,041.28

流动负债:

    短期借款                               857,397,834.91                    1,032,400,428.35

    交易性金融负债

    以公允价值计量且其变动计入当期
损益的金融负债

    衍生金融负债

    应付票据及应付账款                     172,701,834.82                      288,359,109.45

    预收款项                                 7,388,580.69                        6,689,643.40




                                     20
                             深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


    合同负债

    应付职工薪酬                    19,174,400.90                       44,340,032.15

    应交税费                        51,839,981.13                       52,582,783.36

    其他应付款                    1,389,466,627.03                   1,383,594,338.83

      其中:应付利息                17,195,394.69                       10,671,623.26

               应付股利

    持有待售负债

    一年内到期的非流动负债

    其他流动负债

流动负债合计                      2,497,969,259.48                   2,807,966,335.54

非流动负债:

    长期借款                       545,280,000.00                      545,280,000.00

    应付债券                       995,073,224.79                      994,608,157.79

      其中:优先股

               永续债

    租赁负债

    长期应付款

    长期应付职工薪酬

    预计负债

    递延收益                         4,491,928.23                        4,664,271.21

    递延所得税负债                  28,576,535.70                       18,994,793.62

    其他非流动负债

非流动负债合计                    1,573,421,688.72                   1,563,547,222.62

负债合计                          4,071,390,948.20                   4,371,513,558.16

所有者权益:

    股本                          1,247,201,704.00                   1,247,201,704.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                      2,326,254,798.25                   2,291,775,529.98

    减:库存股

    其他综合收益                    50,467,406.36                       32,628,807.75

    专项储备

    盈余公积                       513,125,623.22                      517,566,569.56



                             21
                                              深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


       未分配利润                                  1,733,571,959.48                   1,825,695,871.83

所有者权益合计                                     5,870,621,491.31                   5,914,868,483.12

负债和所有者权益总计                               9,942,012,439.51                  10,286,382,041.28


3、合并利润表

                                                                                                单位:元

                      项目                    本期发生额                       上期发生额

一、营业总收入                                       1,023,118,395.29                   959,291,558.46

       其中:营业收入                                1,023,118,395.29                   959,291,558.46

             利息收入

             已赚保费

             手续费及佣金收入

二、营业总成本                                         966,218,171.02                   856,738,842.33

       其中:营业成本                                  656,245,165.52                   566,249,187.68

             利息支出

             手续费及佣金支出

             退保金

             赔付支出净额

             提取保险合同准备金净额

             保单红利支出

             分保费用

             税金及附加                                    2,615,426.89                     3,992,408.40

             销售费用                                   59,652,196.10                    62,900,141.39

             管理费用                                  101,693,680.68                    81,569,056.69

             研发费用                                   39,576,899.12                    60,962,696.54

             财务费用                                  106,377,729.98                    81,017,684.73

               其中:利息费用                           53,806,751.37                    43,459,519.65

                      利息收入                             5,182,193.49                  23,166,722.70

             资产减值损失                                    57,072.73                         47,666.90

             信用减值损失

       加:其他收益                                        3,816,442.03                     7,403,894.58

           投资收益(损失以“-”号填列)              515,826,217.23                       -9,449,376.32

           其中:对联营企业和合营企业的投资
                                                       -61,842,373.93                   -15,555,043.85
收益



                                              22
                                                  深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


           汇兑收益(损失以“-”号填列)

           净敞口套期收益(损失以“-”号填
列)

           公允价值变动收益(损失以“-”号填
                                                            4,013,061.75
列)

           资产处置收益(损失以“-”号填列)                                                     20,000.00

三、营业利润(亏损以“-”号填列)                        580,555,945.28                    100,527,234.39

       加:营业外收入                                         493,097.48                      1,461,063.16

       减:营业外支出                                         220,143.23                          9,456.06

四、利润总额(亏损总额以“-”号填列)                    580,828,899.53                    101,978,841.49

       减:所得税费用                                      86,280,120.91                     30,617,586.13

五、净利润(净亏损以“-”号填列)                        494,548,778.62                     71,361,255.36

     (一)按经营持续性分类

       1.持续经营净利润(净亏损以“-”号填列)           494,548,778.62                     71,361,255.36

       2.终止经营净利润(净亏损以“-”号填列)

     (二)按所有权属分类

       1.归属于母公司所有者的净利润                       507,033,390.57                     68,850,444.57

       2.少数股东损益                                     -12,484,611.95                      2,510,810.79

六、其他综合收益的税后净额                                -11,378,667.64                   -137,121,113.08

     归属母公司所有者的其他综合收益的税后
                                                          -10,903,267.61                   -135,076,449.93
净额

      (一)不能重分类进损益的其他综合收益                  5,572,533.67

             1.重新计量设定受益计划变动额

             2.权益法下不能转损益的其他综合
收益

             3.其他权益工具投资公允价值变动                 5,572,533.67

             4.企业自身信用风险公允价值变动

             5.其他

       (二)将重分类进损益的其他综合收益                 -16,475,801.28                   -135,076,449.93

             1.权益法下可转损益的其他综合收
                                                           -1,033,631.83


             2.其他债权投资公允价值变动

             3.可供出售金融资产公允价值变动
                                                                                            -84,101,279.95
损益

             4.金融资产重分类计入其他综合收
益的金额


                                                  23
                                                         深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


             5.持有至到期投资重分类为可供出
售金融资产损益

             6.其他债权投资信用减值准备

             7.现金流量套期储备

             8.外币财务报表折算差额                                 -15,442,169.45                   -50,975,169.98

             9.其他

     归属于少数股东的其他综合收益的税后净
                                                                       -475,400.03                    -2,044,663.15


七、综合收益总额                                                    483,170,110.98                   -65,759,857.72

       归属于母公司所有者的综合收益总额                             496,130,122.96                   -66,226,005.36

       归属于少数股东的综合收益总额                                 -12,960,011.98                      466,147.64

八、每股收益:

       (一)基本每股收益                                                  0.4065                           0.0552

       (二)稀释每股收益                                                  0.4065                           0.0552

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:元,上期被合并方实现的净利润为:元。


法定代表人:李锂                            主管会计工作负责人:张斌                       会计机构负责人:张斌


4、母公司利润表

                                                                                                           单位:元

                 项目                              本期发生额                           上期发生额

一、营业收入                                                    409,009,714.22                       362,675,657.49

       减:营业成本                                             309,477,929.23                       269,927,639.87

           税金及附加                                              274,983.17                          1,374,692.65

           销售费用                                               2,285,301.09                         1,483,524.18

           管理费用                                              30,681,321.31                        20,323,207.95

           研发费用                                              13,719,427.79                        12,769,151.34

           财务费用                                              54,379,631.60                        53,630,494.09

               其中:利息费用                                    29,945,012.64                        25,389,645.74

                      利息收入                                   10,611,837.06                        25,665,939.47

           资产减值损失                                             118,977.50

           信用减值损失

       加:其他收益                                               2,896,934.46                         2,881,342.98

           投资收益(损失以“-”号填
                                                                -66,840,632.84                        -7,318,533.23
列)



                                                         24
                                         深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


           其中:对联营企业和合营企
                                              -62,352,830.26                       -13,147,662.53
业的投资收益

           净敞口套期收益(损失以
“-”号填列)

           公允价值变动收益(损失以
                                               4,013,061.75
“-”号填列)

           资产处置收益(损失以“-”号
填列)

二、营业利润(亏损以“-”号填列)            -61,858,494.10                        -1,270,242.84

       加:营业外收入                                                                    3,980.00

       减:营业外支出                             10,086.47                               372.73

三、利润总额(亏损总额以“-”号填
                                              -61,868,580.57                        -1,266,635.57
列)

       减:所得税费用                          -9,870,472.17                          -189,995.34

四、净利润(净亏损以“-”号填列)            -51,998,108.40                        -1,076,640.23

       (一)持续经营净利润(净亏损
                                              -51,998,108.40                        -1,076,640.23
以“-”号填列)

       (二)终止经营净利润(净亏损
以“-”号填列)

五、其他综合收益的税后净额                     -1,033,631.83                       -87,323,645.79

       (一)不能重分类进损益的其他
综合收益

             1.重新计量设定受益计划
变动额

             2.权益法下不能转损益的
其他综合收益

             3.其他权益工具投资公允
价值变动

             4.企业自身信用风险公允
价值变动

             5.其他

       (二)将重分类进损益的其他综
                                               -1,033,631.83                       -87,323,645.79
合收益

             1.权益法下可转损益的其
                                               -1,033,631.83
他综合收益

             2.其他债权投资公允价值
变动

             3.可供出售金融资产公允                                                -87,323,645.79


                                         25
                                            深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


价值变动损益

             4.金融资产重分类计入其
他综合收益的金额

             5.持有至到期投资重分类
为可供出售金融资产损益

             6.其他债权投资信用减值
准备

             7.现金流量套期储备

             8.外币财务报表折算差额

             9.其他

六、综合收益总额                                    -53,031,740.23                     -88,400,286.02

七、每股收益:

       (一)基本每股收益

       (二)稀释每股收益


5、合并现金流量表

                                                                                             单位:元

                 项目                 本期发生额                          上期发生额

一、经营活动产生的现金流量:

       销售商品、提供劳务收到的现金                935,193,243.89                      911,933,092.19

       客户存款和同业存放款项净增
加额

       向中央银行借款净增加额

       向其他金融机构拆入资金净增
加额

       收到原保险合同保费取得的现


       收到再保险业务现金净额

       保户储金及投资款净增加额

       处置以公允价值计量且其变动
计入当期损益的金融资产净增加额

       收取利息、手续费及佣金的现金

       拆入资金净增加额

       回购业务资金净增加额

       代理买卖证券收到的现金净额

       收到的税费返还                               65,348,558.36                       26,459,306.54


                                            26
                                      深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


       收到其他与经营活动有关的现
                                            17,185,635.09                        19,615,039.99


经营活动现金流入小计                    1,017,727,437.34                        958,007,438.72

       购买商品、接受劳务支付的现金        738,420,165.39                       670,595,624.20

       客户贷款及垫款净增加额

       存放中央银行和同业款项净增
加额

       支付原保险合同赔付款项的现


       为交易目的而持有的金融资产
净增加额

       拆出资金净增加额

       支付利息、手续费及佣金的现金

       支付保单红利的现金

       支付给职工以及为职工支付的
                                           219,539,063.85                       186,377,919.61
现金

       支付的各项税费                       49,697,007.15                        44,528,547.40

       支付其他与经营活动有关的现
                                           148,251,774.37                       133,048,227.60


经营活动现金流出小计                    1,155,908,010.76                      1,034,550,318.81

经营活动产生的现金流量净额                 -138,180,573.42                      -76,542,880.09

二、投资活动产生的现金流量:

       收回投资收到的现金                  463,615,546.78                       255,295,968.32

       取得投资收益收到的现金               15,087,855.78                         4,011,183.36

       处置固定资产、无形资产和其他
                                               385,658.04                            20,000.00
长期资产收回的现金净额

       处置子公司及其他营业单位收
到的现金净额

       收到其他与投资活动有关的现


投资活动现金流入小计                       479,089,060.60                       259,327,151.68

       购建固定资产、无形资产和其他
                                           102,508,294.91                       131,315,725.38
长期资产支付的现金

       投资支付的现金                      476,193,506.44                       193,712,890.17

       质押贷款净增加额

       取得子公司及其他营业单位支
付的现金净额


                                      27
                                            深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


       支付其他与投资活动有关的现


投资活动现金流出小计                               578,701,801.35                      325,028,615.55

投资活动产生的现金流量净额                         -99,612,740.75                      -65,701,463.87

三、筹资活动产生的现金流量:

       吸收投资收到的现金                           13,581,800.00

       其中:子公司吸收少数股东投资
                                                    13,581,800.00
收到的现金

       取得借款收到的现金                          682,147,400.65                      577,897,041.39

       发行债券收到的现金

       收到其他与筹资活动有关的现
                                                                                         2,160,386.65


筹资活动现金流入小计                               695,729,200.65                      580,057,428.04

       偿还债务支付的现金                     1,238,481,470.50                         416,502,497.45

       分配股利、利润或偿付利息支付
                                                    47,175,200.75                       34,234,698.33
的现金

       其中:子公司支付给少数股东的
股利、利润

       支付其他与筹资活动有关的现
                                                     3,941,670.07                        4,174,999.43


筹资活动现金流出小计                          1,289,598,341.32                         454,912,195.21

筹资活动产生的现金流量净额                       -593,869,140.67                       125,145,232.83

四、汇率变动对现金及现金等价物的
                                                    -6,051,105.36                       -9,565,708.94
影响

五、现金及现金等价物净增加额                     -837,713,560.20                       -26,664,820.07

       加:期初现金及现金等价物余额           2,117,908,652.77                      3,591,019,281.85

六、期末现金及现金等价物余额                  1,280,195,092.57                      3,564,354,461.78


6、母公司现金流量表

                                                                                             单位:元

                项目                  本期发生额                          上期发生额

一、经营活动产生的现金流量:

       销售商品、提供劳务收到的现金                474,151,627.81                      380,734,060.71

       收到的税费返还                               52,465,045.07                       26,457,401.65

       收到其他与经营活动有关的现
                                                     7,290,558.94                       14,112,103.97



                                            28
                                      深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


经营活动现金流入小计                       533,907,231.82                       421,303,566.33

       购买商品、接受劳务支付的现金        452,048,510.02                       346,663,132.61

       支付给职工以及为职工支付的
                                            66,836,416.29                        57,033,745.96
现金

       支付的各项税费                       20,702,100.63                        15,435,827.38

       支付其他与经营活动有关的现
                                            65,042,481.73                        13,465,326.34


经营活动现金流出小计                       604,629,508.67                       432,598,032.29

经营活动产生的现金流量净额                  -70,722,276.85                      -11,294,465.96

二、投资活动产生的现金流量:

       收回投资收到的现金                  394,415,546.78                       200,528,825.81

       取得投资收益收到的现金               13,886,239.34                         3,982,568.87

       处置固定资产、无形资产和其他
                                                   800.00
长期资产收回的现金净额

       处置子公司及其他营业单位收
到的现金净额

       收到其他与投资活动有关的现


投资活动现金流入小计                       408,302,586.12                       204,511,394.68

       购建固定资产、无形资产和其他
                                            73,972,846.68                        82,068,668.51
长期资产支付的现金

       投资支付的现金                      218,407,984.14                       133,332,163.89

       取得子公司及其他营业单位支
付的现金净额

       支付其他与投资活动有关的现
                                           446,195,515.76


投资活动现金流出小计                       738,576,346.58                       215,400,832.40

投资活动产生的现金流量净额                 -330,273,760.46                      -10,889,437.72

三、筹资活动产生的现金流量:

       吸收投资收到的现金

       取得借款收到的现金                  221,967,260.00                       119,874,386.54

       发行债券收到的现金

       收到其他与筹资活动有关的现


筹资活动现金流入小计                       221,967,260.00                       119,874,386.54

       偿还债务支付的现金                  391,390,393.82                       186,000,000.00



                                      29
                                                           深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


       分配股利、利润或偿付利息支付
                                                                 25,742,625.88                        16,550,276.38
的现金

       支付其他与筹资活动有关的现
                                                                   1,779,967.28                        4,426,288.81


筹资活动现金流出小计                                            418,912,986.98                       206,976,565.19

筹资活动产生的现金流量净额                                      -196,945,726.98                      -87,102,178.65

四、汇率变动对现金及现金等价物的
                                                                  -1,866,563.22                       -1,829,055.41
影响

五、现金及现金等价物净增加额                                    -599,808,327.51                     -111,115,137.74

       加:期初现金及现金等价物余额                          1,624,582,294.97                      3,227,938,630.55

六、期末现金及现金等价物余额                                 1,024,773,967.46                      3,116,823,492.81


二、财务报表调整情况说明

1、首次执行新金融工具准则、新收入准则、新租赁准则调整首次执行当年年初财务报表相关情况

√ 适用 □ 不适用
合并资产负债表
                                                                                                           单位:元

              项目              2018 年 12 月 31 日                2019 年 1 月 1 日             调整数

流动资产:

       货币资金                         2,121,745,382.45                  2,121,745,382.45

       交易性金融资产                 不适用                                116,776,242.73           116,776,242.73

       以公允价值计量且其
变动计入当期损益的金融                     79,215,975.24                不适用                       -79,215,975.24
资产

       应收票据及应收账款               1,085,011,935.13                  1,085,011,935.13

         其中:应收票据                     1,270,000.00                      1,270,000.00

                应收账款                1,083,741,935.13                  1,083,741,935.13

       预付款项                           209,074,315.90                    209,074,315.90

       其他应收款                         208,083,239.67                    208,083,239.67

         其中:应收利息                    68,901,627.36                     68,901,627.36

       存货                             1,529,977,946.64                  1,529,977,946.64

       其他流动资产                       366,908,620.97                    366,908,620.97

流动资产合计                            5,600,017,416.00                  5,637,577,683.49            37,560,267.49

非流动资产:

       可供出售金融资产                 1,604,576,638.19                不适用                    -1,604,576,638.19


                                                           30
                                                 深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


       长期应收款                 7,761,376.21                   7,761,376.21

       长期股权投资            467,291,507.14                  467,291,507.14

       其他权益工具投资     不适用                           1,267,313,099.78            1,267,313,099.78

       其他非流动金融资产   不适用                             352,682,339.44              352,682,339.44

       固定资产               1,607,503,760.60               1,607,503,760.60

       在建工程                743,775,565.82                  743,775,565.82

       无形资产                729,843,416.78                  729,843,416.78

       开发支出                 15,376,337.08                   15,376,337.08

       商誉                   2,316,763,164.90               2,316,763,164.90

       长期待摊费用            212,857,482.57                  212,857,482.57

       递延所得税资产          208,971,292.44                  211,276,146.35                2,304,853.91

       其他非流动资产          140,341,931.62                  140,341,931.62

非流动资产合计                8,055,062,473.35               8,072,786,128.30               17,723,654.95

资产总计                     13,655,079,889.35              13,710,363,811.79               55,283,922.44

流动负债:

       短期借款               1,981,491,046.35               1,981,491,046.35

       应付票据及应付账款      334,974,579.29                  334,974,579.29

       预收款项                 97,806,654.17                   97,806,654.17

       应付职工薪酬            128,119,602.66                  128,119,602.66

       应交税费                 82,201,143.51                   82,201,143.51

       其他应付款             1,361,351,397.17               1,361,351,397.17

         其中:应付利息         19,825,989.68                   19,825,989.68

       一年内到期的非流动
                               485,009,829.14                  485,009,829.14
负债

       其他流动负债             33,519,201.97                   33,519,201.97

流动负债合计                  4,504,473,454.26               4,504,473,454.26

非流动负债:

       长期借款               1,454,833,881.38               1,454,833,881.38

       应付债券                994,608,157.79                  994,608,157.79

       长期应付款                 7,788,409.10                   7,788,409.10

       长期应付职工薪酬         67,139,226.82                   67,139,226.82

       预计负债                   9,696,689.88                   9,696,689.88

       递延收益                 31,254,005.05                   31,254,005.05

       递延所得税负债          340,539,461.52                  350,424,496.79                9,885,035.27




                                                 31
                                                       深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


非流动负债合计                      2,905,859,831.54                2,915,744,866.81               9,885,035.27

负债合计                            7,410,333,285.80                7,420,218,321.07               9,885,035.27

所有者权益:

       股本                         1,247,201,704.00                1,247,201,704.00

       资本公积                     2,254,181,696.10                2,254,181,696.10

       其他综合收益                   108,981,640.76                  129,161,318.24              20,179,677.48

       盈余公积                       517,566,569.56                  517,566,569.56

       未分配利润                   1,940,094,058.22                1,965,313,267.91              25,219,209.69

归属于母公司所有者权益
                                    6,068,025,668.64                6,113,372,643.29              45,346,974.65
合计

       少数股东权益                   176,720,934.91                  176,772,847.43                  51,912.52

所有者权益合计                      6,244,746,603.55                6,290,145,490.72              45,398,887.17

负债和所有者权益总计               13,655,079,889.35               13,710,363,811.79              55,283,922.44

调整情况说明

    财政部于2017年3月31日分别发布了《企业会计准则第22号——金融工具确认和计量(2017年修订)》
(财会〔2017〕7号)、《企业会计准则第23号——金融资产转移(2017年修订)》(财会〔2017〕8号)、
《企业会计准则第24号——套期会计(2017年修订)》(财会〔2017〕9号),于2017年5月2日发布了《企
业会计准则第37号——金融工具列报(2017年修订)》(财会〔2017〕14号)(上述准则以下统称“新金
融工具准则”),并要求境内上市公司自2019年1月1日起施行。经本公司第四届董事会第二十一次会议决
议通过,本公司于2019年1月1日起执行上述新金融工具准则。
母公司资产负债表
                                                                                                       单位:元

              项目          2018 年 12 月 31 日              2019 年 1 月 1 日               调整数

流动资产:

       货币资金                     1,624,582,294.97                1,624,582,294.97

       交易性金融资产             不适用                              116,776,242.73             116,776,242.73

       以公允价值计量且其
变动计入当期损益的金融                 79,215,975.24             不适用                          -79,215,975.24
资产

       应收票据及应收账款           1,537,134,588.92                1,537,134,588.92

         其中:应收票据                96,270,000.00                   96,270,000.00

                应收账款            1,440,864,588.92                1,440,864,588.92

       预付款项                       562,679,752.43                  562,679,752.43

       其他应收款                     612,526,311.64                  612,526,311.64

         其中:应收利息               223,753,432.17                  223,753,432.17

       存货                           363,369,059.84                  363,369,059.84



                                                       32
                                               深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


    其他流动资产            216,124,612.46                   216,124,612.46

流动资产合计               4,995,632,595.50                5,033,192,862.99               37,560,267.49

非流动资产:

    可供出售金融资产        473,911,545.02               不适用                         -473,911,545.02

    长期应收款              961,534,320.00                   961,534,320.00

    长期股权投资           2,548,598,518.15                2,548,598,518.15

    其他权益工具投资     不适用                              458,368,858.11              458,368,858.11

    固定资产                603,513,778.11                   603,513,778.11

    在建工程                437,425,211.96                   437,425,211.96

    无形资产                 98,637,382.26                    98,637,382.26

    开发支出                      281,086.15                      281,086.15

    长期待摊费用             93,935,642.15                    93,935,642.15

    递延所得税资产           66,767,066.28                    66,961,595.58                 194,529.30

    其他非流动资产             6,144,895.70                    6,144,895.70

非流动资产合计             5,290,749,445.78                5,275,401,288.18              -15,348,157.60

资产总计                  10,286,382,041.28               10,308,594,151.17               22,212,109.89

流动负债:

    短期借款               1,032,400,428.35                1,016,857,741.44              -15,542,686.91

    应付票据及应付账款      288,359,109.45                   288,359,109.45

    预收款项                   6,689,643.40                    6,689,643.40

    应付职工薪酬             44,340,032.15                    44,340,032.15

    应交税费                 52,582,783.36                    52,582,783.36

    其他应付款             1,383,594,338.83                1,383,594,338.83

      其中:应付利息         10,671,623.26                    10,671,623.26

流动负债合计               2,807,966,335.54                2,807,966,335.54

非流动负债:

    长期借款                545,280,000.00                   545,280,000.00

    应付债券                994,608,157.79                   994,608,157.79

    递延收益                   4,664,271.21                    4,664,271.21

    递延所得税负债           18,994,793.62                    22,491,960.01                3,497,166.39

非流动负债合计             1,563,547,222.62                1,567,044,389.01                3,497,166.39

负债合计                   4,371,513,558.16                4,375,010,724.55                3,497,166.39

所有者权益:

    股本                   1,247,201,704.00                1,247,201,704.00



                                               33
                                                   深圳市海普瑞药业集团股份有限公司 2019 年第一季度报告全文


     资本公积                   2,291,775,529.98               2,291,775,529.98

     其他综合收益                 32,628,807.75                   51,528,794.70               18,899,986.95

     盈余公积                    517,566,569.56                  517,566,569.56

     未分配利润                 1,825,695,871.83               1,825,510,828.38                 -185,043.45

所有者权益合计                  5,914,868,483.12               5,933,583,426.62               18,714,943.50

负债和所有者权益总计           10,286,382,041.28              10,308,594,151.17               22,212,109.89

调整情况说明

    财政部于2017年3月31日分别发布了《企业会计准则第22号——金融工具确认和计量(2017年修订)》
(财会〔2017〕7号)、《企业会计准则第23号——金融资产转移(2017年修订)》(财会〔2017〕8号)、
《企业会计准则第24号——套期会计(2017年修订)》(财会〔2017〕9号),于2017年5月2日发布了《企
业会计准则第37号——金融工具列报(2017年修订)》(财会〔2017〕14号)(上述准则以下统称“新金
融工具准则”),并要求境内上市公司自2019年1月1日起施行。经本公司第四届董事会第二十一次会议决
议通过,本公司于2019年1月1日起执行上述新金融工具准则。

2、首次执行新金融工具准则、新租赁准则追溯调整前期比较数据的说明

□ 适用 √ 不适用


三、审计报告

第一季度报告是否经过审计
□ 是 √ 否
公司第一季度报告未经审计。




                                                                    深圳市海普瑞药业集团股份有限公司

                                                                                       法定代表人:李锂

                                                                                           2019年4月29日




                                                   34
数据加载中...
prevnext
手机查看股票